Synthetic and natural iron chelators: Therapeutic potential and clinical use

Future Medicinal Chemistry

Volumn 1, Issue 9, 2009, Pages 1643-1670

  Hatcher, Heather C ^a   Singh, Ravi N ^a   Torti, Frank M ^a   Torti, Suzy V ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; APOCYNIN; BAICALEIN; BAICALIN; CLIOQUINOL; CURCUMIN; DEFERASIROX; DEFERIPRONE; DEFEROXAMINE MESYLATE; DEFERRIFERRITHIOCIN; DEXRAZONE; DI 2 PYRIDYLKETONE THIOSEMICARBAZONE; EPIGALLOCATECHIN GALLATE; FLAVAN 3 OL; FLAVAN DERIVATIVE; FLORANOL; GENISTEIN; ICRF 197; IRON CHELATING AGENT; KOLAVIRON; N,N',N'' TRIS(2 PYRIDYLMETHYL) CIS,CIS 1,3,5 TRIAMINOCYCLOHEXANE; PHYTIC ACID; PYRIDOXAL ISONICOTINOYLHYDRAZONE; QUERCETIN; RAZOXANE; SEMICARBAZONE DERIVATIVE; TACHPYRIDINE; TETRAMETHYLPYRAZINE; THEAFLAVIN; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CATALYSIS; CELL GROWTH; CELL PROLIFERATION; CREATINE KINASE BLOOD LEVEL; CYTOPENIA; DEGENERATIVE DISEASE; DISEASE COURSE; GASTROINTESTINAL SYMPTOM; HOMEOSTASIS; HUMAN; IRON CHELATION; IRON OVERLOAD; KIDNEY FAILURE; MAMMAL; NEOPLASM; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PRIORITY JOURNAL; RASH; REVIEW; SIDE EFFECT;

HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; OXIDATIVE STRESS; SIDEROPHORES;

EID: 77953412928     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.121     Document Type: Review

References (247)

1. Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim. Biophys. Acta 1331, 1-40 (1997).
2. Andrews NC. Disorders of iron metabolism. N. Engl. J. Med. 341, 1986-1995 (1999).
3. Lieu PT, Heiskala M, Peterson PA, Yang Y. The roles of iron in health and disease. Mol. Aspects Med. 22, 1-87 (2001).
4. Richardson DR. Therapeutic potential of iron chelators in cancer therapy. Adv. Exp. Med. Biol. 509, 231-249 (2002).
5. Hentze MW, Muckenthaler MU, Andrews NC. Balancing acts: molecular control of mammalian iron metabolism. Cell 117, 285-297 (2004).
6. Aisen P, Enns C, Wessling-Resnick M. Chemistry and biology of eukaryotic iron metabolism. Int. J. Biochem. Cell Biol. 33, 940-959 (2001).
7. Kalinowski DS, Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol. Rev. 57, 547-583 (2005).
8. Buss JL, Torti FM, Torti SV. The role of iron chelation in cancer therapy. Curr. Med. Chem. 10, 1021-1034 (2003).
9. Buss JL, Greene BT, Turner J, Torti FM, Torti SV. Iron chelators in cancer chemotherapy. Curr. Top. Med. Chem. 4, 1623-1635 (2004).
10. Galaris D, Pantopoulos K. Oxidative stress and iron homeostasis: mechanistic and health aspects. Crit. Rev. Clin. Lab. Sci. 45, 1-23 (2008).
11. Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem. J. 219, 1-14 (1984).
12. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol. 186, 1-85 (1990).
13. Andrews NC. Forging a field: the golden age of iron biology. Blood 112, 219-230 (2008).
14. Conrad ME, Umbreit JN. Pathways of iron absorption. Blood Cells Mol. Dis. 29, 336-355 (2002).
15. Donovan A, Brownlie A, Zhou Y et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 403, 776-781 (2000).
16. Donovan A, Lima CA, Pinkus JL et al. The iron exporter ferroportin/Slc40a1 is essential for iron homeostasis. Cell Metab. 1, 191-200 (2005).
17. Ganz T. Cellular iron: ferroportin is the only way out. Cell Metab. 1, 155-157 (2005).
18. Vulpe CD, Kuo YM, Murphy TL et al. Hephaestin, a ceruloplasmin homologue implicated in intestinal iron transport, is defective in the SLA mouse. Nat. Genet. 21, 195-199 (1999).
19. Ohgami RS, Campagna DR, Greer EL et al. Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat. Genet. 37, 1264-1269 (2005).
20. Fleming MD, Romano MA, Su MA, Garrick LM, Garrick MD, Andrews NC. Nramp2 is mutated in the anemic Belgrade (b) rat: evidence of a role for Nramp2 in endosomal iron transport. Proc. Natl Acad. Sci. USA 95, 1148-1153 (1998).
21. Fleming MD, Trenor CC 3rd, Su MA et al. Microcytic anaemia mice have a mutation in Nramp2, a candidate iron transporter gene. Nat. Genet. 16, 383-386 (1997).
22. Gunshin H, Mackenzie B, Berger UV et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 388, 482-488 (1997).
23. Kawabata H, Nakamaki T, Ikonomi P, Smith RD, Germain RS, Koeffler HP. Expression of transferrin receptor 2 in normal and neoplastic hematopoietic cells. Blood 98, 2714-2719 (2001).
24. Kawabata H, Tong X, Kawanami T et al. Analyses for binding of the transferrin family of proteins to the transferrin receptor 2. Br. J. Haematol. 127, 464-473 (2004).
25. Barton JC. Optimal management strategies for chronic iron overload. Drugs 67, 685-700 (2007).
26. Hider RC, Zhou T. The design of orally active iron chelators. Ann. NY Acad. Sci. 1054, 141-154 (2005).
27. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med. Genomics 2, 2 (2009).
28. Knovich MA, Storey JA, Coffman LG, Torti SV, Torti FM. Ferritin for the clinician. Blood Rev. 23, 95-104 (2009).
29. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacol. Rev. 60, 79-127 (2008).
30. Ryter SW, Alam J, Choi AM. Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications. Physiol. Rev. 86, 583-650 (2006).
31. Vitek L, Schwertner HA. The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases. Adv. Clin. Chem. 43, 1-57 (2007).
32. De Domenico I, Ward DM, Langelier C et al. The molecular mechanism of hepcidinmediated ferroportin down-regulation. Mol. Biol. Cell 18, 2569-2578 (2007).
33. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306, 2090-2093 (2004).
34. Ganz T, Nemeth E. Iron imports. IV. Hepcidin and regulation of body iron metabolism. Am. J. Physiol. Gastrointest. Liver Physiol. 290, G199-G203 (2006).
35. Wang RH, Li C, Xu X et al. A role of SMAD4 in iron metabolism through the positive regulation of hepcidin expression. Cell Metab. 2, 399-409 (2005).
36. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 109, 353-358 (2007).
37. Wrighting DM, Andrews NC. Interleukin-6 induces hepcidin expression through STAT3. Blood 108, 3204-3209 (2006).
38. Choi SO, Cho YS, Kim HL, Park JW. ROS mediate the hypoxic repression of the hepcidin gene by inhibiting C/EBPa and STAT-3. Biochem. Biophys. Res. Commun. 356, 312-317 (2007).
39. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 99, 3505-3516 (2002).
40. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim. Biophys. Acta. 1275, 161-203 (1996).
41. Arosio P, Yokota M, Drysdale JW. Characterization of serum ferritin in iron overload: possible identity to natural apoferritin. Br. J. Haematol. 36, 199-207 (1977).
42. Coffman LG, Parsonage D, D'Agostino R Jr, Torti FM, Torti SV. Regulatory effects of ferritin on angiogenesis. Proc. Natl Acad. Sci. USA 106, 570-575 (2009).
43. Peyssonnaux C, Nizet V, Johnson RS. Role of the hypoxia inducible factors HIF in iron metabolism. Cell Cycle 7, 28-32 (2008).
44. O'Rourke JF, Pugh CW, Bartlett SM, Ratcliffe PJ. Identification of hypoxically inducible mRNAs in HeLa cells using differentialdisplay PCR. Role of hypoxia-inducible factor-1. Eur. J. Biochem. 241, 403-410 (1996).
45. Triantafyllou A, Liakos P, Tsakalof A et al. The flavonoid quercetin induces hypoxia-inducible factor-1a (HIF-1a) and inhibits cell proliferation by depleting intracellular iron. Free Radic. Res. 41, 342-356 (2007).
46. Jeon H, Kim H, Choi D et al. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol. Pharmacol. 71, 1676-1684 (2007).
47. Liu ZD, Hider RC. Design of clinically useful iron(III)-selective chelators. Med. Res. Rev. 22, 26-64 (2002).
48. Porter JB. Evaluation of new iron chelators for clinical use. Acta. Haematol. 95, 13-25 (1996).
49. Le NT, Richardson DR. Competing pathways of iron chelation: angiogenesis or anti-tumor activity: targeting different molecules to induce specific effects. Int. J. Cancer 110, 468-469 (2004).
50. Yu Y, Wong J, Lovejoy DB, Kalinowski DS, Richardson DR. Chelators at the cancer coalface: desferrioxamine to Triapine and beyond. Clin. Cancer Res. 12, 6876-6883 (2006).
51. Tang TY, Howarth SP, Miller SR et al. Comparison of the inflammatory burden of truly asymptomatic carotid atheroma with atherosclerotic plaques in patients with asymptomatic carotid stenosis undergoing coronary artery bypass grafting: an ultrasmall superparamagnetic iron oxide enhanced magnetic resonance study. Eur. J. Vasc. Endovasc. Surg. 35, 392-398 (2008).
52. Deugnier Y, Brissot P, Loreal O. Iron and the liver: update 2008. J. Hepatol. 48(Suppl. 1), S113-S123 (2008).
53. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr. Opin. Infect. Dis. 21, 620-625 (2008).
54. Hider RC, Ma Y, Molina-Holgado F, Gaeta A, Roy S. Iron chelation as a potential therapy for neurodegenerative disease. Biochem. Soc. Trans. 36, 1304-1308 (2008).
55. Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care 30, 1926-1933 (2007).
56. Li L, Frei B. Prolonged exposure to LPS increases iron, heme, and p22phox levels and NADPH oxidase activity in human aortic endothelial cells: inhibition by desferrioxamine. Arterioscler. Thromb. Vasc. Biol. 29, 732-738 (2009).
57. Sullivan JL. Iron in arterial plaque: a modifiable risk factor for atherosclerosis. Biochim. Biophys. Acta 1790(7), 718-723 (2008).
58. Haas H, Eisendle M, Turgeon BG. Siderophores in fungal physiology and virulence. Annu. Rev. Phytopathol. 46, 149-187 (2008).
59. Askwith CC, de Silva D, Kaplan J. Molecular biology of iron acquisition in Saccharomyces cerevisiae. Mol. Microbiol. 20, 27-34 (1996).
60. Vermylen C. What is new in iron overload? Eur. J. Pediatr. 167, 377-381 (2008).
61. Nick H. Iron chelation, quo vadis? Curr. Opin. Chem. Biol. 11, 419-423 (2007).
62. Beutler E. Iron storage disease: facts, fiction and progress. Blood Cells Mol. Dis. 39, 140-147 (2007).
63. Reeder BJ, Hider RC, Wilson MT. Iron chelators can protect against oxidative stress through ferryl heme reduction. Free Radic. Biol. Med. 44, 264-273 (2008).
64. Turner JJ, Rice-Evans CA, Davies MJ, Newman ES. Free radicals, myocytes and reperfusion injury. Biochem. Soc. Trans. 18, 1056-1059 (1990).
65. Miller YI, Felikman Y, Shaklai N. Hemoglobin induced apolipoprotein B crosslinking in low-density lipoprotein peroxidation. Arch. Biochem. Biophys. 326, 252-260 (1996).
66. Reeder BJ, Wilson MT. Desferrioxamine inhibits production of cytotoxic heme to protein cross-linked myoglobin: a mechanism to protect against oxidative stress without iron chelation. Chem. Res. Toxicol. 18, 1004-1011 (2005).
67. Maggio A. Light and shadows in the iron chelation treatment of haematological diseases. Br. J. Haematol. 138, 407-421 (2007).
68. Delea TE, Edelsberg J, Sofrygin O et al. Consequences and costs of noncompliance with iron chelation therapy in patients with transfusion-dependent thalassemia: a literature review. Transfusion 47, 1919-1929 (2007).
69. Anderson LJ, Westwood MA, Holden S et al. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Br. J. Haematol. 127, 348-355 (2004).
70. Borgna-Pignatti C, Cappellini MD, De Stefano P et al. Cardiac morbidity and mortality in deferoxamine-or deferipronetreated patients with thalassemia major. Blood 107, 3733-3737 (2006).
71. Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 104, 263-269 (2004).
72. Porter JB. Concepts and goals in the management of transfusional iron overload. Am. J. Hematol. 82, 1136-1139 (2007).
73. Porter JB, Huehns ER. Transfusion and exchange transfusion in sickle cell anaemias, with particular erence to iron metabolism. Acta Haematol. 78, 198-205 (1987).
74. Leitch HA. Improving clinical outcome in patients with myelodysplastic syndrome and iron overload using iron chelation therapy. Leuk. Res. 31(Suppl. 3), S7-S9 (2007).
75. Cazzola M, Malcovati L. Myelodysplastic syndromes -coping with ineffective hematopoiesis. N. Engl. J. Med. 352, 536-538 (2005).
76. Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer 106, 2087-2094 (2006).
77. Gattermann N. Guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Leuk. Res. 31(Suppl. 3), S10-S15 (2007).
78. Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney disease. J. Am. Soc. Nephrol. 18, 16-28 (2007).
79. Aigner E, Theurl I, Theurl M et al. Pathways underlying iron accumulation in human nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 87, 1374-1383 (2008).
80. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Semin. Liver Dis. 25, 433-449 (2005).
81. Swaminathan S, High WA, Ranville J et al. Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int. 73, 1413-1418 (2008).
82. de Vries B, Walter SJ, von Bonsdorff L et al. Reduction of circulating redox-active iron by apotransferrin protects against renal ischemia-reperfusion injury. Transplantation 77, 669-675 (2004).
83. Yuan XM, Li W. Iron involvement in multiple signaling pathways of atherosclerosis: a revisited hypothesis. Curr. Med. Chem. 15, 2157-2172 (2008).
84. Ren M, Rajendran R, Ning P et al. Zinc supplementation decreases the development of atherosclerosis in rabbits. Free Radic. Biol. Med. 41, 222-225 (2006).
85. Ferrara DE, Taylor WR. Iron chelation and vascular function: in search of the mechanisms. Arterioscler. Thromb. Vasc. Biol. 25, 2235-2237 (2005).
86. Ishizaka N, Saito K, Mori I, Matsuzaki G, Ohno M, Nagai R. Iron chelation suppresses ferritin upregulation and attenuates vascular dysfunction in the aorta of angiotensin II-infused rats. Arterioscler. Thromb. Vasc. Biol. 25, 2282-2288 (2005).
87. Cutler P. Deferoxamine therapy in high-ferritin diabetes. Diabetes 38, 1207-1210 (1989).
88. Nitenberg A, Ledoux S, Valensi P, Sachs R, Antony I. Coronary microvascular adaptation to myocardial metabolic demand can be restored by inhibition of iron-catalyzed formation of oxygen free radicals in type 2 diabetic patients. Diabetes 51, 813-818 (2002).
89. Dongiovanni P, Valenti L, Ludovica Fracanzani A, Gatti S, Cairo G, Fargion S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am. J. Pathol. 172, 738-747 (2008).
90. Platis O, Anagnostopoulos G, Farmaki K, Posantzis M, Gotsis E, Tolis G. Glucose metabolism disorders improvement in patients with thalassaemia major after 24-36 months of intensive chelation therapy. Pediatr. Endocrinol. Rev. 2(Suppl. 2), 279-281 (2004).
91. Zheng Y, Li XK, Wang Y, Cai L. The role of zinc, copper and iron in the pathogenesis of diabetes and diabetic complications: therapeutic effects by chelators. Hemoglobin 32, 135-145 (2008).
92. Christoforidis A, Perifanis V, Athanassiou-Metaxa M. Combined chelation therapy improves glucose metabolism in patients with b-thalassaemia major. Br. J. Haematol. 135, 271-272 (2006).
93. Christoforidis A, Perifanis V, Tsatra I, Vlachaki E, Athanassiou-Metaxa M. Evolution of OGTT in patients with b-thalassaemia major in relation to chelation therapy. Diabetes Res. Clin. Pract. 76, 6-11 (2007).
94. Farmaki K, Angelopoulos N, Anagnostopoulos G, Gotsis E, Rombopoulos G, Tolis G. Effect of enhanced iron chelation therapy on glucose metabolism in patients with b-thalassaemia major. Br. J. Haematol. 134, 438-444 (2006).
95. Pahl PM, Horwitz LD. Cell permeable iron chelators as potential cancer chemotherapeutic agents. Cancer Invest. 23, 683-691 (2005).
96. Brard L, Granai CO, Swamy N. Iron chelators deferoxamine and diethylenetriamine pentaacetic acid induce apoptosis in ovarian carcinoma. Gynecol. Oncol. 100, 116-127 (2006).
97. Hoke EM, Maylock CA, Shacter E. Desferal inhibits breast tumor growth and does not interfere with the tumoricidal activity of doxorubicin. Free Radic. Biol. Med. 39, 403-411 (2005).
98. Lee SK, Lee J, Min SK et al. Iron chelator differentially activates macrophage inflammatory protein-3a/CCL20 in immortalized and malignant human oral keratinocytes. Arch. Oral Biol. 53, 801-809 (2008).
99. Richardson DR, Kalinowski DS, Lau S, Jansson PJ, Lovejoy DB. Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim. Biophys. Acta 1790(7), 702-717 (2008).
100. Bergeron RJ, Wiegand J, Dionis JB et al. Evaluation of desferrithiocin and its synthetic analogues as orally effective iron chelators. J. Med. Chem. 34, 2072-2078 (1991).
101. Kicic A, Chua AC, Baker E. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents. Anticancer Drug Des. 16, 195-207 (2001).
102. Kicic A, Chua AC, Baker E. Desferrithiocin is a more potent antineoplastic agent than desferrioxamine. Br. J. Pharmacol. 135, 1393-1402 (2002).
103. Bergeron RJ, Streiff RR, Creary EA et al. A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model. Blood 81, 2166-2173 (1993).
104. Kattamis A, Ladis V, Berdousi H et al. Iron chelation treatment with combined therapy with deferiprone and deferioxamine: a 12-month trial. Blood Cells Mol. Dis. 36, 21-25 (2006).
105. Sajid R, Ghani F, Adil S, Khurshid M. Oral iron chelation therapy with deferiprone in patients with Thalassemia Major. J. Pak. Med. Assoc. 59, 388-390 (2009).
106. Molina-Holgado F, Gaeta A, Francis PT, Williams RJ, Hider RC. Neuroprotective actions of deferiprone in cultured cortical neurones and SHSY-5Y cells. J. Neurochem. 105(6), 2466-2476 (2008).
107. Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron 39, 889-909 (2003).
108. Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB. Neuroprotective strategies in Parkinson's disease: an update on progress. CNS Drugs 17, 729-762 (2003).
109. Whitnall M, Richardson DR. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin. Pediatr. Neurol. 13, 186-197 (2006).
110. Cherny RA, Atwood CS, Xilinas ME et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits b-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 30, 665-676 (2001).
111. Kaur D, Yantiri F, Rajagopalan S et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37, 899-909 (2003).
112. Liu G, Men P, Harris PL, Rolston RK, Perry G, Smith MA. Nanoparticle iron chelators: a new therapeutic approach in Alzheimer disease and other neurologic disorders associated with trace metal imbalance. Neurosci. Lett. 406, 189-193 (2006).
113. Shen AY, Wu SN, Chiu CT. Synthesis and cytotoxicity evaluation of some 8-hydroxyquinoline derivatives. J. Pharm. Pharmacol. 51, 543-548 (1999).
114. Gaboriau F, Laupen-Chassay C, Pasdeloup N, Pierre JL, Brissot P, Lescoat G. Modulation of cell proliferation and polyamine metabolism in rat liver cell cultures by the iron chelator O-trensox. Biometals 19, 623-632 (2006).
115. Rakba N, Loyer P, Gilot D et al. Antiproliferative and apoptotic effects of O-trensox, a new synthetic iron chelator, on differentiated human hepatoma cell lines. Carcinogenesis 21, 943-951 (2000).
116. Ballardini G, Groff P, Zoli M et al. Increased risk of hepatocellular carcinoma development in patients with cirrhosis and with high hepatocellular proliferation. J. Hepatol. 20, 218-222 (1994).
117. Tarao K, Shimizu A, Ohkawa S et al. Development of hepatocellular carcinoma associated with increases in DNA synthesis in the surrounding cirrhosis. Gastroenterology 103, 595-600 (1992).
118. Cappellini MD, Cohen A, Piga A et al. A Phase III study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with b-thalassemia. Blood 107, 3455-3462 (2006).
119. Piga A, Galanello R, Forni GL et al. Randomized Phase II trial of deferasirox (Exjade, ICL670), a once-daily, orallyadministered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 91, 873-880 (2006).
120. Vichinsky E. Clinical application of deferasirox: practical patient management. Am. J. Hematol. 83, 398-402 (2008).
121. Yang LP, Keam SJ, Keating GM. Deferasirox: a review of its use in the management of transfusional chronic iron overload. Drugs 67, 2211-2230 (2007).
122. Porter J, Galanello R, Saglio G et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur. J. Haematol. 80, 168-176 (2008).
123. Torti SV, Torti FM, Whitman SP, Brechbiel MW, Park G, Planalp RP. Tumor cell cytotoxicity of a novel metal chelator. Blood 92, 1384-1389 (1998).
124. Zhao R, Planalp RP, Ma R et al. Role of zinc and iron chelation in apoptosis mediated by tachpyridine, an anti-cancer iron chelator. Biochem. Pharmacol. 67, 1677-1688 (2004).
125. Chong HS, Torti SV, Ma R, Torti FM, Brechbiel MW. Synthesis and potent antitumor activities of novel 1,3,5-cis,cistriaminocyclohexane N-pyridyl derivatives. J. Med. Chem. 47, 5230-5234 (2004).
126. Turner J, Koumenis C, Kute TE et al. Tachpyridine, a metal chelator, induces G2 cell-cycle arrest, activates checkpoint kinases, and sensitizes cells to ionizing radiation. Blood 106, 3191-3199 (2005).
127. Childers ML, Cho J, Regino CA et al. Influence of ligand structure on Fe(II) spin-state and redox rate in cytotoxic tripodal chelators. J. Inorg. Biochem. 102, 150-156 (2008).
128. Hasinoff BB, Herman EH. Dexrazoxane: how it works in cardiac and tumor cells. Is it a prodrug or is it a drug? Cardiovasc. Toxicol. 7, 140-144 (2007).
129. Herman EH, Ferrans VJ. Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy. Cancer Treat. Rev. 17, 155-160 (1990).
130. Swain SM, Vici P. The current and future role of dexrazoxane as a cardioprotectant in anthracycline treatment: expert panel review. J. Cancer Res. Clin. Oncol. 130, 1-7 (2004).
131. Hasinoff BB, Hellmann K, Herman EH, Ferrans VJ. Chemical, biological and clinical aspects of dexrazoxane and other bisdioxopiperazines. Curr. Med. Chem. 5, 1-28 (1998).
132. Hasinoff BB, Schroeder PE, Patel D. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity. Mol. Pharmacol. 64, 670-678 (2003).
133. Hasinoff BB. Dexrazoxane (ICRF-187) protects cardiac myocytes against hypoxiareoxygenation damage. Cardiovasc. Toxicol. 2, 111-118 (2002).
134. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K, Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone, administered by 96-hour intravenous continuous infusion. J. Clin. Oncol. 22, 1553-1563 (2004).
135. Shao J, Zhou B, Zhu L et al. In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. Cancer Res. 64, 1-6 (2004).
136. Barker CA, Burgan WE, Carter DJ et al. In vitro and in vivo radiosensitization induced by the ribonucleotide reductase inhibitor Triapine (3-aminopyridine-2-carboxaldehydethiosemicarbazone). Clin. Cancer Res. 12, 2912-2918 (2006).
137. Yen Y, Margolin K, Doroshow J et al. A Phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother. Pharmacol. 54, 331-342 (2004).
138. Yee KW, Cortes J, Ferrajoli A et al. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk. Res. 30, 813-822 (2006).
139. Lovejoy DB, Richardson DR. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators. Curr. Med. Chem. 10, 1035-1049 (2003).
140. Simunek T, Klimtova I, Kaplanova J et al. Study of daunorubicin cardiotoxicity prevention with pyridoxal isonicotinoyl hydrazone in rabbits. Pharmacol. Res. 51, 223-231 (2005).
141. Darnell G, Richardson DR. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents III. The effect of the ligands on molecular targets involved in proliferation. Blood 94, 781-792 (1999).
142. Debebe Z, Ammosova T, Jerebtsova M et al. Iron chelators ICL670 and 311 inhibit HIV-1 transcription. Virology 367, 324-333 (2007).
143. Becker EM, Lovejoy DB, Greer JM, Watts R, Richardson DR. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents. Br. J. Pharmacol. 138, 819-830 (2003).
144. Chaston TB, Watts RN, Yuan J, Richardson DR. Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin. Cancer Res. 10, 7365-7374 (2004).
145. Bernhardt PV, Wilson GJ, Sharpe PC, Kalinowski DS, Richardson DR. Tuning the antiproliferative activity of biologically active iron chelators: characterization of the coordination chemistry and biological efficacy of 2-acetylpyridine and 2-benzoylpyridine hydrazone ligands. J. Biol. Inorg. Chem. 13, 107-119 (2008).
146. Yuan J, Lovejoy DB, Richardson DR. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104, 1450-1458 (2004).
147. Noulsri E, Richardson DR, Lerdwana S et al. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am. J. Hematol. 84, 170-176 (2009).
148. Rao VA, Klein SR, Agama KK et al. The iron chelator Dp44mT causes DNA damage and selective inhibition of topoisomerase IIa in breast cancer cells. Cancer Res. 69, 948-957 (2009).
149. Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc. Natl Acad. Sci. USA 103, 14901-14906 (2006).
150. Hatcher H, Planalp R, Cho J, Torti FM, Torti SV. Curcumin: from ancient medicine to current clinical trials. Cell Mol. Life Sci. 65, 1631-1652 (2008).
151. Hider RC, Liu ZD, Khodr HH. Metal chelation of polyphenols. Methods Enzymol. 335, 190-203 (2001).
152. Morel I, Lescoat G, Cogrel P et al. Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures. Biochem. Pharmacol. 45, 13-19 (1993).
153. Guo M, Harvey I, Yang W et al. Synergistic anion and metal binding to the ferric ion-binding protein from Neisseria gonorrhoeae. J. Biol. Chem. 278, 2490-2502 (2003).
154. Baker HM, Anderson BF, Baker EN. Dealing with iron: common structural principles in proteins that transport iron and heme. Proc. Natl Acad. Sci. USA 100, 3579-3583 (2003).
155. Alexeev D, Zhu H, Guo M et al. A novel protein-mineral interface. Nat. Struct. Biol. 10, 297-302 (2003).
156. Guo M, Harvey I, Campopiano DJ, Sadler PJ. Short oxo-titanium(IV) bond in bacterial transferrin: a protein target for metalloantibiotics. Angew. Chem. Int. Ed. Engl. 45, 2758-2761 (2006).
157. Raymond KN, Dertz EA, Kim SS. Enterobactin: an archetype for microbial iron transport. Proc. Natl Acad. Sci. USA 100, 3584-3588 (2003).
158. Zhu H, Alexeev D, Hunter DJ, Campopiano DJ, Sadler PJ. Oxo-iron clusters in a bacterial iron-trafficking protein: new roles for a conserved motif. Biochem. J. 376, 35-41 (2003).
159. Heim KE, Tagliaferro AR, Bobilya DJ. Flavonoid antioxidants: chemistry, metabolism and structure-activity relationships. J. Nutr. Biochem. 13, 572-584 (2002).
160. Rao YK, Geethangili M, Fang SH, Tzeng YM. Antioxidant and cytotoxic activities of naturally occurring phenolic and related compounds: a comparative study. Food Chem. Toxicol. 45, 1770-1776 (2007).
161. Hu JP, Calomme M, Lasure A et al. Structure-activity relationship of flavonoids with superoxide scavenging activity. Biol. Trace Elem. Res. 47, 327-331 (1995).
162. Manach C, Williamson G, Morand C, Scalbert A, Remesy C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am. J. Clin. Nutr. 81, 230S-242S (2005).
163. Williamson G, Manach C. Bioavailability and bioefficacy of polyphenols in humans. II. Review of 93 intervention studies. Am. J. Clin. Nutr. 81, 243S-255S (2005).
164. Khanbabaee K, van Ree T. Tannins: classification and definition. Nat. Prod. Rep. 18, 641-649 (2001).
165. Aron PM, Kennedy JA. Flavan-3-ols: nature, occurrence and biological activity. Mol. Nutr. Food Res. 52, 79-104 (2008).
166. Cos P, De Bruyne T, Hermans N, Apers S, Berghe DV, Vlietinck AJ. Proanthocyanidins in health care: current and new trends. Curr. Med. Chem. 11, 1345-1359 (2004).
167. Havsteen BH. The biochemistry and medical significance of the flavonoids. Pharmacol. Ther. 96, 67-202 (2002).
168. Messina M, Kucuk O, Lampe JW. An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. J. AOAC Int. 89, 1121-1134 (2006).
169. Shoji T, Akazome Y, Kanda T, Ikeda M. The toxicology and safety of apple polyphenol extract. Food Chem. Toxicol. 42, 959-967 (2004).
170. Jiao Y, Wilkinson Jt, Di X et al. Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator. Blood 113, 462-469 (2009).
171. Bernabe-Pineda M, Ramirez-Silva MT, Romero-Romo MA, Gonzalez-Vergara E, Rojas-Hernandez A. Spectrophotometric and electrochemical determination of the formation constants of the complexes Curcumin-Fe(III)-water and Curcumin-Fe(II)-water. Spectrochim. Acta A Mol. Biomol. Spectrosc. 60, 1105-1113 (2004).
172. Jiao Y, Wilkinson Jt, Christine Pietsch E et al. Iron chelation in the biological activity of curcumin. Free Radic. Biol. Med. 40, 1152-1160 (2006).
173. Thephinlap C, Phisalaphong C, Fucharoen S, Porter JB, Srichairatanakool S. Efficacy of curcuminoids in alleviation of iron overload and lipid peroxidation in thalassemic mice. Med. Chem. 5(5), 474-482 (2009).
174. Dhanasekaran M, Tharakan B, Manyam BV. Antiparkinson drug -mucuna pruriens shows antioxidant and metal chelating activity. Phytother. Res. 22, 6-11 (2008).
175. Mandel SA, Avramovich-Tirosh Y, Reznichenko L et al. Multifunctional activities of green tea catechins in neuroprotection. Modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals 14, 46-60 (2005).
176. Rathore P, Dohare P, Varma S et al. Curcuma oil: reduces early accumulation of oxidative product and is anti-apoptogenic in transient focal ischemia in rat brain. Neurochem. Res. 33, 1672-1682 (2008).
177. Kahles T, Luedike P, Endres M et al. NADPH oxidase plays a central role in blood-brain barrier damage in experimental stroke. Stroke 38, 3000-3006 (2007).
178. Tang LL, Ye K, Yang XF, Zheng JS. Apocynin attenuates cerebral infarction after transient focal ischaemia in rats. J. Int. Med. Res. 35, 517-522 (2007).
179. Wang Q, Tompkins KD, Simonyi A, Korthuis RJ, Sun AY, Sun GY. Apocynin protects against global cerebral ischemia-reperfusioninduced oxidative stress and injury in the gerbil hippocampus. Brain Res. 1090, 182-189 (2006).
180. Sun AY, Wang Q, Simonyi A, Sun GY. Botanical phenolics and brain health. Neuromolecular. Med. 10, 259-274 (2008).
181. Farombi EO, Nwaokeafor IA. Anti-oxidant mechanisms of kolaviron: studies on serum lipoprotein oxidation, metal chelation and oxidative membrane damage in rats. Clin. Exp. Pharmacol. Physiol. 32, 667-674 (2005).
182. Botelho FV, Alvarez-Leite JI, Lemos VS et al. Physicochemical study of floranol, its copper(II) and iron(III) complexes, and their inhibitory effect on LDL oxidation. J. Inorg. Biochem. 101, 935-943 (2007).
183. Packer L, Rimbach G, Virgili F. Antioxidant activity and biologic properties of a procyanidin-rich extract from pine (Pinus maritima) bark, pycnogenol. Free Radic. Biol. Med. 27, 704-724 (1999).
184. Maffei Facino R, Carini M, Aldini G et al. Procyanidines from Vitis vinifera seeds protect rabbit heart from ischemia/reperfusion injury: antioxidant intervention and/or iron and copper sequestering ability. Planta. Med. 62, 495-502 (1996).
185. Yoshino M, Murakami K. Interaction of iron with polyphenolic compounds: application to antioxidant characterization. Anal. Biochem. 257, 40-44 (1998).
186. Perez CA, Wei Y, Guo M. Iron-binding and anti-Fenton properties of baicalein and baicalin. J. Inorg. Biochem. 103, 326-332 (2009).
187. Lee HZ, Leung HW, Lai MY, Wu CH. Baicalein induced cell cycle arrest and apoptosis in human lung squamous carcinoma CH27 cells. Anticancer Res. 25, 959-964 (2005).
188. Lee JH, Li YC, Ip SW et al. The role of Ca2+ in baicalein-induced apoptosis in human breast MDA-MB-231 cancer cells through mitochondria-and caspase-3-dependent pathway. Anticancer Res. 28, 1701-1711 (2008).
189. Zhang Y, Li H, Zhao Y, Gao Z. Dietary supplementation of baicalin and quercetin attenuates iron overload induced mouse liver injury. Eur. J. Pharmacol. 535, 263-269 (2006).
190. Zhao Y, Li H, Gao Z, Xu H. Effects of dietary baicalin supplementation on iron overload-induced mouse liver oxidative injury. Eur. J. Pharmacol. 509, 195-200 (2005).
191. Guo M, Perez C, Wei Y et al. Iron-binding properties of plant phenolics and cranberry's bio-effects. Dalton Trans. 21(43), 4951-4961 (2007).
192. Zhang Z, Wei T, Hou J, Li G, Yu S, Xin W. Iron-induced oxidative damage and apoptosis in cerebellar granule cells: attenuation by tetramethylpyrazine and ferulic acid. Eur. J. Pharmacol. 467, 41-47 (2003).
193. Feng L, Ke N, Cheng F et al. The protective mechanism of ligustrazine against renal ischemia/reperfusion injury. J. Surg. Res. (2009).
194. Feng L, Xiong Y, Cheng F, Zhang L, Li S, Li Y. Effect of ligustrazine on ischemiareperfusion injury in murine kidney. Transplant Proc. 36, 1949-1951 (2004).
195. Moridani MY, Pourahmad J, Bui H, Siraki A, O'Brien PJ. Dietary flavonoid iron complexes as cytoprotective superoxide radical scavengers. Free Radic. Biol. Med. 34, 243-253 (2003).
196. Spencer JP, Abd-el-Mohsen MM, Rice-Evans C. Cellular uptake and metabolism of flavonoids and their metabolites: implications for their bioactivity. Arch. Biochem. Biophys. 423, 148-161 (2004).
197. Yan X, Murphy BT, Hammond GB, Vinson JA, Neto CC. Antioxidant activities and antitumor screening of extracts from cranberry fruit (Vaccinium macrocarpon). J. Agric. Food Chem. 50, 5844-5849 (2002).
198. Porter ML, Krueger CG, Wiebe DA, Cunningham DG, Reed JD. Cranberry proanthocyanidins associate with low-density lipoprotein and inhibit in vitro Cu2+-induced oxidation. J. Sci. Food Agric. 81, 1306-1313 (2001).
199. Neto CC, Sweeney-Nixon MI, Lamoureaux TL, Solomon F, Kondo M, MacKinnon SL. Cranberry Phenolics: Effects on Oxidative Processes, Neuron Cell Death and Tumor Cell Growth. ACS Books, Columbus, OH, USA 271-282 (2005).
200. Youdim KA, McDonald J, Kalt W, Joseph JA. Potential role of dietary flavonoids in reducing microvascular endothelium vulnerability to oxidative and inflammatory insults (small star, filled). J. Nutr. Biochem. 13, 282-288 (2002).
201. Seeram NP, Adams LS, Hardy ML, Heber D. Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. J. Agric. Food Chem. 52, 2512-2517 (2004).
202. Bagchi D, Sen CK, Ray SD et al. Molecular mechanisms of cardioprotection by a novel grape seed proanthocyanidin extract. Mutat. Res. 523-524, 87-97 (2003).
203. Frederiksen H, Mortensen A, Schroder M et al. Effects of red grape skin and seed extract supplementation on atherosclerosis in Watanabe heritable hyperlipidemic rabbits. Mol. Nutr. Food Res. 51, 564-571 (2007).
204. Kim EY, Ham SK, Shigenaga MK, Han O. Bioactive dietary polyphenolic compounds reduce nonheme iron transport across human intestinal cell monolayers. J. Nutr. 138, 1647-1651 (2008).
205. Sato M, Maulik G, Ray PS, Bagchi D, Das DK. Cardioprotective effects of grape seed proanthocyanidin against ischemic reperfusion injury. J. Mol. Cell Cardiol. 31, 1289-1297 (1999).
206. Reznichenko L, Amit T, Zheng H et al. Reduction of iron-regulated amyloid precursor protein and b-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J. Neurochem. 97, 527-536 (2006).
207. Cai F, Li CR, Wu JL et al. Theaflavin ameliorates cerebral ischemia-reperfusion injury in rats through its anti-inflammatory effect and modulation of STAT-1. Mediators Inflamm. 2006, 30490 (2006).
208. Guo Q, Zhao B, Li M, Shen S, Xin W. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim. Biophys. Acta 1304, 210-222 (1996).
209. Kumamoto M, Sonda T, Nagayama K, Tabata M. Effects of pH and metal ions on antioxidative activities of catechins. Biosci. Biotechnol. Biochem. 65, 126-132 (2001).
210. Grinberg LN, Newmark H, Kitrossky N, Rahamim E, Chevion M, Rachmilewitz EA. Protective effects of tea polyphenols against oxidative damage to red blood cells. Biochem. Pharmacol. 54, 973-978 (1997).
211. Friedman M, Mackey BE, Kim HJ et al. Structure-activity relationships of tea compounds against human cancer cells. J. Agric. Food Chem. 55, 243-253 (2007).
212. Lahiry L, Saha B, Chakraborty J et al. Contribution of p53-mediated Bax transactivation in theaflavin-induced mammary epithelial carcinoma cell apoptosis. Apoptosis 13, 771-781 (2008).
213. Lu J, Gosslau A, Liu AY, Chen KY. PCR differential display-based identification of regulator of G protein signaling 10 as the target gene in human colon cancer cells induced by black tea polyphenol theaflavin monogallate. Eur. J. Pharmacol. 601, 66-72 (2008).
214. Cao X, Qin J, Xie Y et al. Regulator of G-protein signaling 2 (RGS2) inhibits androgen-independent activation of androgen receptor in prostate cancer cells. Oncogene 25, 3719-3734 (2006).
215. Kelly P, Moeller BJ, Juneja J et al. The G12 family of heterotrimeric G proteins promotes breast cancer invasion and metastasis. Proc. Natl Acad. Sci. USA 103, 8173-8178 (2006).
216. Kaur S, Greaves P, Cooke DN et al. Breast cancer prevention by green tea catechins and black tea theaflavins in the C3(1) SV40 T,t antigen transgenic mouse model is accompanied by increased apoptosis and a decrease in oxidative DNA adducts. J. Agric. Food Chem. 55, 3378-3385 (2007).
217. Rogers AE, Hafer LJ, Iskander YS, Yang S. Black tea and mammary gland carcinogenesis by 7,12-dimethylbenz[a]anthracene in rats fed control or high fat diets. Carcinogenesis 19, 1269-1273 (1998).
218. Weisburger JH, Rivenson A, Garr K, Aliaga C. Tea, or tea and milk, inhibit mammary gland and colon carcinogenesis in rats. Cancer Lett. 114, 323-327 (1997).
219. Zhou JR, Yu L, Mai Z, Blackburn GL. Combined inhibition of estrogen-dependent human breast carcinoma by soy and tea bioactive components in mice. Int. J. Cancer 108, 8-14 (2004).
220. Banerjee S, Manna S, Mukherjee S, Pal D, Panda CK, Das S. Black tea polyphenols restrict benzopyrene-induced mouse lung cancer progression through inhibition of Cox-2 and induction of caspase-3 expression. Asian Pac. J. Cancer Prev. 7, 661-666 (2006).
221. Mandel S, Weinreb O, Reznichenko L, Kalfon L, Amit T. Green tea catechins as brain-permeable, non toxic iron chelators to "iron out iron" from the brain. J. Neural Transm. Suppl. 71, 249-257 (2006).
222. Mandel SA, Amit T, Kalfon L, Reznichenko L, Youdim MB. Targeting multiple neurodegenerative diseases etiologies with multimodal-acting green tea catechins. J. Nutr. 138, 1578S-1583S (2008).
223. Lee S, Suh S, Kim S. Protective effects of the green tea polyphenol (-)-epigallocatechin gallate against hippocampal neuronal damage after transient global ischemia in gerbils. Neurosci. Lett. 287, 191-194 (2000).
224. Sutherland BA, Shaw OM, Clarkson AN, Jackson DN, Sammut IA, Appleton I. Neuroprotective effects of (-)-epigallocatechin gallate following hypoxia-ischemia-induced brain damage: novel mechanisms of action. FASEB. J. 19, 258-260 (2005).
225. Aktas O, Prozorovski T, Smorodchenko A et al. Green tea epigallocatechin-3-gallate mediates T cellular NF-k B inhibition and exerts neuroprotection in autoimmune encephalomyelitis. J. Immunol. 173, 5794-5800 (2004).
226. Haque AM, Hashimoto M, Katakura M, Tanabe Y, Hara Y, Shido O. Long-term administration of green tea catechins improves spatial cognition learning ability in rats. J. Nutr. 136, 1043-1047 (2006).
227. Rezai-Zadeh K, Shytle D, Sun N et al. Green tea epigallocatechin-3- gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J. Neurosci. 25, 8807-8814 (2005).
228. Weinreb O, Amit T, Youdim MB. A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Radic. Biol. Med. 43, 546-556 (2007).
229. Crouse JR 3rd, Morgan T, Terry JG, Ellis J, Vitolins M, Burke GL. A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch. Intern. Med. 159, 2070-2076 (1999).
230. Hanson LN, Engelman HM, Alekel DL, Schalinske KL, Kohut ML, Reddy MB. Effects of soy isoflavones and phytate on homocysteine, C-reactive protein, and iron status in postmenopausal women. Am. J. Clin. Nutr. 84, 774-780 (2006).
231. Vitolins MZ, Anthony M, Burke GL. Soy protein isoflavones, lipids and arterial disease. Curr. Opin. Lipidol. 12, 433-437 (2001).
232. Sullivan JL. Iron and the sex difference in heart disease risk. Lancet 1, 1293-1294 (1981).
233. Hurrell RF, Juillerat MA, Reddy MB, Lynch SR, Dassenko SA, Cook JD. Soy protein, phytate, and iron absorption in humans. Am. J. Clin. Nutr. 56, 573-578 (1992).
234. Reddy MB, Hurrell RF, Juillerat MA, Cook JD. The influence of different protein sources on phytate inhibition of nonhemeiron absorption in humans. Am. J. Clin. Nutr. 63, 203-207 (1996).
235. Swain JH, Alekel DL, Dent SB, Peterson CT, Reddy MB. Iron indexes and total antioxidant status in response to soy protein intake in perimenopausal women. Am. J. Clin. Nutr. 76, 165-171 (2002).
236. Mahesha HG, Singh SA, Rao AG. Inhibition of lipoxygenase by soy isoflavones: evidence of isoflavones as redox inhibitors. Arch. Biochem. Biophys. 461, 176-185 (2007).
237. Su Y, Simmen FA, Xiao R, Simmen RC. Expression profiling of rat mammary epithelial cells reveals candidate signaling pathways in dietary protection from mammary tumors. Physiol. Genomics 30, 8-16 (2007).
238. Davis J, Higginbotham A, O'Connor T et al. Soy protein and isoflavones influence adiposity and development of metabolic syndrome in the obese male ZDF rat. Ann. Nutr. Metab. 51, 42-52 (2007).
239. Davis J, Iqbal MJ, Steinle J et al. Soy protein influences the development of the metabolic syndrome in male obese ZDFxSHHF rats. Horm. Metab. Res. 37, 316-325 (2005).
240. Davis J, Steinle J, Higginbotham DA, Oitker J, Peterson RG, Banz WJ. Soy protein influences insulin sensitivity and cardiovascular risk in male lean SHHF rats. Horm. Metab. Res. 37, 309-315 (2005).
241. Mezei O, Banz WJ, Steger RW, Peluso MR, Winters TA, Shay N. Soy isoflavones exert antidiabetic and hypolipidemic effects through the PPAR pathways in obese Zucker rats and murine RAW 264.7 cells. J. Nutr. 133, 1238-1243 (2003).
242. Peluso MR, Winters TA, Shanahan MF, Banz WJ. A cooperative interaction between soy protein and its isoflavone-enriched fraction lowers hepatic lipids in male obese Zucker rats and reduces blood platelet sensitivity in male Sprague-Dawley rats. J. Nutr. 130, 2333-2342 (2000).
243. Kwiatkowski JL. Oral iron chelators. Pediatr. Clin. North Am. 55, 461-482 (2008).
244. Devanur LD, Evans RW, Evans PJ, Hider RC. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy. Biochem. J. 409, 439-447 (2008).
245. Fabio G, Minonzio F, Delbini P, Bianchi A, Cappellini MD. Reversal of cardiac complications by deferiprone and deferoxamine combination therapy in a patient affected by a severe type of juvenile hemochromatosis (JH). Blood 109, 362-364 (2007).
246. Peng CT, Chow KC, Chen JH, Chiang YP, Lin TY, Tsai CH. Safety monitoring of cardiac and hepatic systems in b-thalassemia patients with chelating treatment in Taiwan. Eur. J. Haematol. 70, 392-397 (2003).
247. Halliwell B. Dietary polyphenols: good, bad, or indifferent for your health? Cardiovasc. Res. 73, 341-347 (2007).